人源正交IL-2与IL-2Rβ系统在小鼠白血病模型中增强CAR T细胞扩增及抗肿瘤活性
研究构建了含人特异性突变的人源正交IL-2(ortho-hIL-2)与人源正交IL-2Rβ(ortho-hIL-2Rβ)配对系统,ortho-hIL-2对表达ortho-hIL-2Rβ的细胞具有选择性且对野生型T细胞无明显信号传导。在荷CD19+ Nalm6白血病异种移植瘤的免疫缺陷小鼠中,ortho-hIL-2使ortho-hIL-2Rβ+ CAR T细胞在过继转移后2周内呈剂量依赖性扩增,最高达1000倍,并可挽救次优CAR T细胞剂量的抗白血病效应及复发后失败的治疗反应。
要点
- ortho-hIL-2对表达ortho-hIL-2Rβ的细胞具有选择性,对野生型T细胞无明显信号传导。
- ortho-hIL-2支持IL-2依赖性细胞系及转导表达ortho-hIL-2Rβ的原代T细胞增殖。
- 在荷CD19+ Nalm6白血病异种移植瘤的免疫缺陷小鼠中,ortho-hIL-2使ortho-hIL-2Rβ+ CAR T细胞过继转移后2周内呈剂量依赖性扩增,最高达1000倍。
核心结论
- 正交细胞因子方法与人T细胞免疫治疗联用具有增强工程化T细胞抗肿瘤疗效的潜力。
研究设计与样本
- 研究构建含人特异性突变的人源正交IL-2(ortho-hIL-2)与人源正交IL-2Rβ(ortho-hIL-2Rβ)配对系统。
- 在IL-2依赖性细胞系及转导表达ortho-hIL-2Rβ的原代T细胞中评估信号传导与增殖支持。
- 在荷CD19+ Nalm6白血病异种移植瘤的免疫缺陷小鼠中,使用CD19特异性CAR T细胞评估体内扩增与抗白血病效应。
主要发现
- ortho-hIL-2对表达ortho-hIL-2Rβ的细胞具有选择性,对野生型T细胞无明显信号传导。
- ortho-hIL-2诱导IL-2受体信号并支持IL-2依赖性细胞系及转导表达ortho-hIL-2Rβ的原代T细胞增殖。
- 在荷CD19+ Nalm6白血病异种移植瘤的免疫缺陷小鼠中,ortho-hIL-2使ortho-hIL-2Rβ+ CAR T细胞在过继转移后2周内呈剂量依赖性扩增,最高达1000倍。
- ortho-hIL-2可挽救次优CAR T细胞剂量的抗白血病效应。
- 在CAR T细胞治疗后白血病复发时给予ortho-hIL-2,可挽救原本失败抗白血病反应。
临床怎么用
- 原文结论指出正交细胞因子方法与人T细胞免疫治疗联用具有增强工程化T细胞抗肿瘤疗效的潜力,未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interleukin-2 (IL-2) is a central T cell cytokine that promotes T cell proliferation and effector function; however, toxicity due to its pluripotency limits its application to enhance CAR T cell immunotherapy. Previously, mouse IL-2 and its cognate receptor were engineered to create an orthogonal (ortho) cytokine-cytokine receptor pair capable of delivering an IL-2 signal without toxicity. Here, we engineered a human orthogonal IL-2 (ortho-hIL-2) and human orthogonal IL-2Rβ (ortho-hIL-2Rβ) pair, containing human-specific mutations. Ortho-hIL-2 is selective toward ortho-hIL-2Rβ–expressing cells with no appreciable signaling on wild-type T cells. Ortho-hIL-2 induces IL-2 receptor signaling and supports proliferation of both an IL-2–dependent cell line and primary T cells transduced to express the ortho-hIL-2Rβ. Using CD19-specific chimeric antigen receptor (CAR) T cells, we show that ortho-hIL-2 induces a dose-dependent increase in ortho-hIL-2Rβ+ CAR T cell expansion in vivo by as much as 1000-fold at 2 weeks after adoptive transfer into immunodeficient mice bearing CD19+ Nalm6 leukemia xenografts. Ortho-hIL-2 can rescue the antileukemic effect of an otherwise suboptimal CAR T cell dose. In addition, ortho-hIL-2 administration initiated at the time of leukemic relapse after CAR T cell therapy can rescue an otherwise failed antileukemic response. These data highlight the potential of combining an orthogonal cytokine approach with T cell–based immunotherapies to augment the antitumor efficacy of engineered T cells.
引用
- Zhang Q, Hresko ME, Picton LK, et al. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci Transl Med. 2021. PMID: 34936380. doi:10.1126/scitranslmed.abg6986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。